- Home
- MFA vs NUVB Comparison
MFA vs NUVB Comparison
Compare MFA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- NUVB
- Stock Information
- Founded
- MFA 1997
- NUVB 2018
- Country
- MFA United States
- NUVB United States
- Employees
- MFA N/A
- NUVB N/A
- Industry
- MFA Real Estate Investment Trusts
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- NUVB Health Care
- Exchange
- MFA Nasdaq
- NUVB Nasdaq
- Market Cap
- MFA 1.1B
- NUVB 959.2M
- IPO Year
- MFA N/A
- NUVB N/A
- Fundamental
- Price
- MFA $10.11
- NUVB $2.51
- Analyst Decision
- MFA Buy
- NUVB Strong Buy
- Analyst Count
- MFA 4
- NUVB 6
- Target Price
- MFA $13.75
- NUVB $7.00
- AVG Volume (30 Days)
- MFA 1.3M
- NUVB 3.0M
- Earning Date
- MFA 02-20-2025
- NUVB 02-27-2025
- Dividend Yield
- MFA 13.86%
- NUVB N/A
- EPS Growth
- MFA N/A
- NUVB N/A
- EPS
- MFA 1.60
- NUVB N/A
- Revenue
- MFA $366,192,000.00
- NUVB $2,162,000.00
- Revenue This Year
- MFA N/A
- NUVB N/A
- Revenue Next Year
- MFA $14.93
- NUVB $369.72
- P/E Ratio
- MFA $6.31
- NUVB N/A
- Revenue Growth
- MFA 164.50
- NUVB N/A
- 52 Week Low
- MFA $9.36
- NUVB $1.44
- 52 Week High
- MFA $13.45
- NUVB $4.16
- Technical
- Relative Strength Index (RSI)
- MFA 43.29
- NUVB 42.25
- Support Level
- MFA $9.36
- NUVB $2.44
- Resistance Level
- MFA $10.40
- NUVB $2.77
- Average True Range (ATR)
- MFA 0.22
- NUVB 0.23
- MACD
- MFA 0.03
- NUVB -0.04
- Stochastic Oscillator
- MFA 61.57
- NUVB 6.40
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).